Although both TROP-2 and EpCAM predict a poor prognosis when overexpressed in breast and ovarian cancers, in small-sized adenocarcinoma they have opposite biological effects, with TROP-2 having a negative prognostic effect while EpCAM indicating a favorable prognosis [64]. This evidence concerns the gene EPCAM and ovarian carcinoma.